Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1204)	4/19/2001 3:23:47 PM
From: Ian@SI	Respond to of 1321

QLT Announces Visudyne™ Sales for First Quarter of 2001 QUARTERLY GROWTH IN SALES EXCEEDS 20% FOR THIRD CONSECUTIVE QUARTER FOR IMMEDIATE RELEASE APRIL 19, 2001 VANCOUVER, CANADA - Following today’s release of first quarter sales for 2001 by Novartis AG (NYSE:NVS), QLT Inc. (NASDAQ:QLTI; TSE:QLT) reported global Visudyne™ sales of approximately US$48 million (CDN$73.5 million or 80 million Swiss Francs) for the quarter ended March 31, 2001. This compares to global Visudyne sales of US$38 million (CDN$58 million or 66 million Swiss Francs) in the fourth quarter of 2000, representing approximately 26% quarterly increase. QLT expects to release its full financial results on Wednesday, April 25, 2001, at 1:00 p.m. EST. Preliminary estimates of net income for the quarter indicate that the Company should record profitability above the high-end range of current analyst expectations. "We are pleased that the continued efforts of our marketing partner, Novartis Ophthalmics, and acceptance of Visudyne therapy by retinal specialists has resulted in the third consecutive quarter of greater than 20% growth in Visudyne sales," said Dr. Julia Levy, QLT’s President and Chief Executive Officer. "In the first 12 months since the product was launched, total Visudyne sales have exceeded US$140 million, making Visudyne the most successful ophthalmic pharmaceutical product based on first year sales. More importantly, retinal specialists in over 35 countries have now performed more than 120,000 treatments with Visudyne therapy." Overall growth in global Visudyne sales of approximately 26% over the fourth quarter of 2000 was consistent with market research results previously released by QLT projecting increased usage by physicians. Commercial Visudyne sales in the United States for the quarter were approximately US$31 million (CDN$47.5 million or 51.5 million Swiss Francs), representing approximately 65% of total sales for the quarter. The remaining US$17 million (CDN$26 million or 28.5 million Swiss Francs) was related to sales in Canada, Europe and other markets. QLT expects that its share of Visudyne net profits (excluding the reimbursement for manufacturing and other costs) for the first quarter will be approximately 21% of total Visudyne sales. QLT’s revenue from Visudyne sales consists of reimbursement for manufacturing, third-party royalties and other costs along with 50% of the Visudyne net profits which are calculated as sales less marketing, overhead and manufacturing costs. QLT Inc. is a world leader in photodynamic therapy, a field of medicine utilizing light-activated drugs in the treatment of disease. QLT’s innovative science has led to the development and commercialization of breakthrough treatments utilizing this technology for applications in ophthalmology and oncology and is exploring the potential in immune disorders. QLT Inc. will hold an analyst and institutional investor conference call to discuss first quarter results on Wednesday, April 25, at 4:30 p.m. EST (1:30 p.m. PST). The call will be broadcast live via the Internet at www.qltinc.com. A replay of the call will be available via the Internet and also via telephone at (416) 626-4100, access code 18478353.